Lycia Therapeutics, Inc. (NASDAQ:LYCA – Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of the stock in a transaction on Monday, November 2nd. The shares were acquired at an average cost of $26.95 per share, for a total transaction of $223,819.75. Following the completion of the transaction, the insider directly owned 6,858,542 shares in the company, valued at $184,837,706.90. The trade was a 0.12% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Friday, October 30th, Venrock Healthcare Capital Par acquired 9,004 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $26.28 per share, for a total transaction of $236,625.12.
- On Thursday, October 29th, Venrock Healthcare Capital Par bought 1,000 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $26.33 per share, with a total value of $26,330.00.
- On Wednesday, October 28th, Venrock Healthcare Capital Par bought 15,000 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $25.45 per share, with a total value of $381,750.00.
- On Tuesday, October 27th, Venrock Healthcare Capital Par bought 39,796 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $26.62 per share, with a total value of $1,059,369.52.
- On Monday, October 26th, Venrock Healthcare Capital Par bought 1,952,705 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $18.04 per share, with a total value of $35,226,798.20.
- On Friday, October 23rd, Venrock Healthcare Capital Par purchased 52,939 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $25.91 per share, for a total transaction of $1,371,649.49.
Lycia Therapeutics Price Performance
Shares of NASDAQ LYCA traded up $1.32 during midday trading on Wednesday, reaching $28.92. 302,655 shares of the company were exchanged, compared to its average volume of 371,219. Lycia Therapeutics, Inc. has a 1 year low of $22.19 and a 1 year high of $36.49.
Analysts Set New Price Targets
Separately, Wall Street Zen raised Lycia Therapeutics to a “hold” rating in a research report on Saturday.
Check Out Our Latest Analysis on LYCA
Lycia Therapeutics Company Profile
Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.
Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.
Featured Articles
- Five stocks we like better than Lycia Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
